UNSPSC 51144008: Fencamfamin hydrochloride

This classification denotes a dopamine agonist with the molecular formula C15H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M1J60BWEX, chemically known as 2-norbornanamine, n-ethyl-3-phenyl-, hydrochloride but more generally known as fencamfamin hydrochloride, which bears US NIH Compound Identifier 14584. European Medicines Agency schedules Fencamfamin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02110MIG.

Most nations, for tariff and trade purposes, schedule fencamfamin hydrochloride under HS 29214600. As of Q4 2014, FENCAMFAMIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fencamfamin hydrochloride bears US NLM identifiers UMLS ID C0140010 and NCI Concept Code C76051. SMILES: CCNC1C2CCC(C2)C1C3CCCCC3.CL.

UNSPSC 51144008 Fencamfamin hydrochloride is a Commodity code that in recent state and local procurement activity describes the supply of pharmaceutical products and drug-management systems to public health agencies. The recent solicitations under this code show a divergence between the nominal chemical name and the actual scope of state and local purchasing: Seminole County, Florida sought naloxone and safe drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription fulfillment programs, and the Minnesota Multistate Cooperative Purchasing Alliance solicited generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local facilities. The issuing bodies span county health departments, state health agencies, and multi-state cooperative purchasing consortia. The work involves both procurement of finished pharmaceutical inventory and exploration of alternative distribution and contracting models that bypass traditional pharmacy benefit managers and wholesalers.

Geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP cooperative extending to Oregon and other participating jurisdictions. The most recent concrete opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, with a bid deadline of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option and requires vendors to manage all shipping and delivery costs. The Minnesota MMCAP RFP (S1070000015802), posted January 20, 2026, with proposals due March 26, 2026, seeks generic pharmaceuticals and OTC products through authorized wholesalers with awards effective July 1, 2026, and evaluates on price competitiveness (75 percent) alongside administrative compliance and EDI capability. The Texas HHS RFI (HHS0017013), posted April 3, 2026, represents preliminary market research rather than a formal competitive solicitation, designed to inform the state's future strategy on direct-to-manufacturer prescription fulfillment.